PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 77 filers reported holding PARATEK PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,671,028 | -12.6% | 657,885 | -35.7% | 0.82% | -27.8% |
| Q4 2022 | $1,912,028 | -23.3% | 1,022,475 | +5.4% | 1.13% | -26.0% |
| Q3 2022 | $2,492,000 | +5.3% | 969,698 | 0.0% | 1.53% | +9.7% |
| Q2 2022 | $2,366,000 | +1.6% | 969,698 | +23.7% | 1.39% | +29.4% |
| Q1 2022 | $2,328,000 | -6.9% | 783,731 | +40.7% | 1.08% | -13.2% |
| Q4 2021 | $2,500,000 | +32.1% | 556,832 | +43.0% | 1.24% | +45.4% |
| Q3 2021 | $1,893,000 | +20.0% | 389,440 | +68.3% | 0.85% | +45.1% |
| Q2 2021 | $1,578,000 | +17.0% | 231,372 | +21.1% | 0.59% | -10.2% |
| Q1 2021 | $1,349,000 | +12.8% | 191,093 | 0.0% | 0.65% | -30.9% |
| Q4 2020 | $1,196,000 | +28.2% | 191,093 | +10.8% | 0.95% | +23.8% |
| Q3 2020 | $933,000 | +15.8% | 172,537 | -0.9% | 0.76% | +7.7% |
| Q1 2017 | $806,000 | +848.2% | 174,176 | +1177.0% | 0.71% | +688.9% |
| Q4 2016 | $85,000 | – | 13,640 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |